MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/iju5.12734

Медицинская библиотека · IJU case reports · 2024

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.

Yanagida Kazuki, Kawai Taketo, Seito Toyoshi, Matsumoto Kensuke, Kaneko Tomoyuki, Nakagawa Tohru

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum-containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and hyperglycemia. However, there are no reports on the development of myelodysplastic syndrome during enfortumab vedotin therapy in clinical settings.

CASE PRESENTATION: A 72-year-old male patient experienced prolonged and severe thrombocytopenia 18 weeks after the start of enfortumab vedotin therapy for metastatic urothelial carcinoma, requiring daily platelet transfusions. Bone marrow examination and chromosomal analysis confirmed the diagnosis of myelodysplastic syndrome. Treatment with eltrombopag proved to be effective.

CONCLUSION

This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.

Для цитирования: Yanagida Kazuki, Kawai Taketo, Seito Toyoshi, Matsumoto Kensuke, Kaneko Tomoyuki, Nakagawa Tohru. Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.. IJU case reports. 2024. DOI: 10.1002/iju5.12734.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.